Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR | P04035 | 6/20 | 0.43 |
| ▸ | PTPN7 | P35236 | 4/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2933749 | 1.00 | HMGCR (0.43) | HMGCRPTPN7TSHRKDM4EALDH1A1 | |
| SCHEMBL3030008 | 0.90 | HMGCR (0.49) | HMGCRPTPN7TSHRRECQLTDP1 | |
| SCHEMBL10540472 | 0.90 | HMGCR (0.49) | HMGCRPTPN7TSHRRECQLTDP1 | |
| SCHEMBL28437823 | 0.90 | HMGCR (0.49) | HMGCRPTPN7TSHRRECQLTDP1 | |
| SCHEMBL1533719 | 0.84 | HMGCR (0.42) | HMGCRPTPN7TSHRKDM4EALDH1A1 | |
| SCHEMBL4763127 | 0.82 | HMGCR (0.33) | HMGCRTSHR | |
| SCHEMBL6852096 | 0.82 | — | — | |
| SCHEMBL11180416 | 0.81 | HMGCR (0.43) | HMGCRPTPN7TSHRRECQLTDP1 | |
| SCHEMBL8157636 | 0.81 | HMGCR (0.41) | HMGCRPTPN7RECQLTDP1 | |
| SCHEMBL8385155 | 0.80 | HMGCR (0.44) | HMGCRPTPN7TSHRKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HMGCR 2048/4885PTPN7 1279/4885TSHR 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.